Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best high short interest stocks with huge upside potential. On June 30, ...

A large, well-capitalized peer is apparently interested in a partnership deal with the company. The media outlet in question ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Fintel reports that on July 1, 2025, UBS initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a Buy recommendation.

After several PD-1xVEGF competitors forged alliances with Big Pharma players, Summit Therapeutics, the frontrunner in this hot cancer drug field, is reportedly seeking its own deal. | After several PD ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...

Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...

Kevin Tang's Concentra Biosciences lines up deal for flailing cancer cell therapy company Cargo Therapeutics — potentially ...